[News Space=Reporter seungwon lee] Biopharmaceutical company Medytox (CEO Jeong Hyeon-ho) announced through its performance disclosure on the 13th that it achieved sales (consolidated basis) of KRW 228.6 billion, operating profit of KRW 20 billion, and net profit of KRW 15.8 billion in 2024.

Sales, operating profit, and net profit increased by 3.4%, 15.6%, and 63.5%, respectively, compared to the previous year.

Medytox has renewed its highest sales record for two consecutive years due to the strong performance of its main business division, hyaluronic acid filler, and the growth of its neuroderma cosmetic, Neuroderm. Operating profit has also improved due to reduced payment commissions.

In detail, the filler division recorded stable sales growth, growing 17% and 5% year-on-year both domestically and overseas. The toxin division decreased 9% overseas and 4% domestically due to the decrease in the operating rate of Plant 1 in the third quarter and the delay in GMP recertification in some export countries in the fourth quarter.

However, as Factory 3 began producing overseas exports in earnest in the second half of last year, the export dependency on Factory 1 is expected to gradually improve starting this year.

Medytox plans to further strengthen its global presence with the next-generation toxin product 'Newlux' from its affiliate Newmeco, which established a mass production system by adding Building E of Osong Plant 3 last year. 'Newlux', which took its first step into the global market by obtaining approval in Peru and Thailand last year, is preparing to leap forward as a global brand with the goal of obtaining approval in about 20 countries this year.

In addition, 'Coretox', which has grown into a main product of Medytox, is expected to expand its market share through mass supply as it added Building E of Plant 3 as a manufacturing plant last month. In addition, it has set a goal of renewing its best performance ever this year through hyaluronic acid fillers 'Neuramis' and 'Attier', which have shown steady sales growth, and 'Neuradem', which has emerged as a new growth engine by advancing into offline stores such as Chicor following the momentum of selling out on home shopping.

A Medytox official said, “2025 will be an important turning point for Medytox to become a global company, with the full-scale overseas expansion of ‘Newlux’ and the application for US FDA approval of the next-generation non-animal liquid toxin product ‘MT10109L.’” He added, “We will do our best to ensure that the related plans are prepared for a long time and lead to results that exceed expectations.”

In addition, he added, “In order to live up to Medytox’s symbol of being the first in Korea and the only one in the world, we will continue to develop a pipeline with differentiated competitiveness, such as ‘PF30’ in the form of a prefilled syringe (PFS) that will bring innovation to the toxin market in the future, and ‘MT951’, a genetically modified toxin preparation.”